A road to original innovation
With our firm mission:to develop drugs that patients await, Green Valley has developed its unique innovation concept: "Insist on self-innovation centered on originality".
Inspired by our fascinating mission “to develop drugs that patients await", Green Valley has attracted a group of brain-related neuroscientists with shared values and built up the Green Valley Research Institute, with aiming to develop a series of original innovations through pathogenesis study, diagnosis research and medicine development in the therapeutic area of brain diseases. By working together with shared values in the area of brain-related neuroscience following the road to original innovation, these scientists are enabling us to achieve scientific leadership in the area of brain disease diagnosis and treatment across the world.
The road to original innovation is to create a unique path for success via making impossible possible. First of all, belief paradigm is the key to innovation. It is only with a grand vision to conquer human diseases and with deep insight that there are possible limitations modern life science can’t solve for human health, and an open mind in scientific research, can we make further progress in shaping new ideas, developing new theories and creating new methods and directions, as well as integrating all wisdom and concepts to explore the mysteries of life, and in hence forming a revolutionarily new belief paradigm for life science. This is the origin of our innovative road and fundamental principle for our innovations in the future.
Firstly, the innovation in belief paradigm requires re-thinking the concept of life essence. Life doesn’t just refer to a biological one, a healthy life means being completely well both physically and spiritually. Secondly, the transformation of innovative epistemology. Reductionism research methods of modern western science has achieved a lot, but its limitations have been increasingly highlighted, especially in the treatment of complex chronic diseases. Over the past decades, the total failure of hundreds of millions of dollars invested in medication research for Alzheimer's disease have seen the truth that the only way to walk out of dilemma is going back to research method of systematic holism. Thirdly, transformation of treatment methods. The asymmetry of the pathogenesis and treatment of complex chronic diseases are the focal points of the contradiction of modern medical science. In terms of methodology, it is impossible to make a breakthrough in drug innovation unless by changing ‘one drug for one target’ into multi-target ones. Rather than small molecular medicines and antibody therapeutics, Green Valley is dedicated to discovering valuable substance to develop multi-target medicines, which is a ‘gold mine’ for our medication research. Fourthly, only integrated solutions containing both diagnosis and treatment can we realize precise treatment and provide patients with great therapeutic value. Fifthly, a series of advanced technologies guaranteed our success of innovation, which are developed according to above creative concepts. With a paradigm shift in the understanding of life essence as well as epistemology and methodology of innovation, Green Valley is trying its best to discover pathogenesis of complex chronic diseases, and develop revolutionarily novel medicines and therapies, which will definitely pave our way to original innovations. Our efforts in pathogenesis discovery and innovative medicines development will provide modern life science with a brand new direction to step out of current dilemmas. From now on, a new paradigm of life science have been growing up, which is believed to bring revolutionary and meaningful changes to human health.
Since our establishment, Green Valley has always adhered to the innovative conception of cooperation and win-win mindset, and has established extensive strategic cooperation with healthcare institutes domestically and overseas. In particular, we embraces long-term strategic partnership with the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. During the period of 20-year cooperation, Salvianolate, a typically important milestone of Chinese traditional medicine modernization, was put into market and saved millions of patients’ lives with co-efforts of Shanghai Institute of Materia Medica and Green Valley. Moreover, we developed GV-971, a novel multi-target medicine for Alzheimer’s disease, along with the Shanghai Institute of Materia Medica and the Ocean University of China. In addition, Shanghai Institute of Materia Medica also provides technical and talent support for the development of our Green Valley Research Institute, which is a unique innovation engine to enable us achieve great breakthroughs on the way to original innovation.
The road to original innovation requires firm belief, sense of responsibility, open mind, continuous innovation, as well as win-win mindset. It is only in this way that Green Valley can attract best talents who recognize our corporate culture and values, and build up an innovative organization with a soul of originality. With strong motivation inside, the company is committed to developing innovative medicines and healthcare solutions that patients await.